Caredx, Inc. (CDNA) Stock Price & Analysis

Caredx, Inc. (CDNA) rose 2.05% to USD 50.88 as of September 8, 2026 at 04:58 UTC, according to Nexqual real-time market data.

CDNA last closed at USD 50.88; the session ranged USD 48.75–50.99 on volume of 1,307,394 shares. Market capitalization is —, with a 52-week range of USD 13.12–53.67 (NGM). Source: Nexqual, September 8, 2026 at 04:58 UTC.

Key Statistics (as of September 8, 2026 at 04:58 UTC)

Technical Analysis (CDNA)

Nexqual's technical model rates CDNA "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 04:58 UTC.

From Caredx, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• Each HeartCare test provides our proprietary Personalized Risk Report, combining measures of immune activation and graft injury for more precise risk assessment.
• Our manufacturing facility in Fremantle, Australia, was used to support the production, packaging and labeling of our proprietary AlloSeq brand kits.
• Intellectual Property Patents and Proprietary Technology To remain competitive, we seek to develop and maintain protection on the proprietary aspects of our technologies.
• Department of Health and Human Services, or HHS, has issued regulations to protect the privacy and security of protected health information, or PHI, and standardize data content, codes and formats used in healthcare transactions and the standardized identifiers used by healthcare providers, such as us, and health plans.  We have developed policies and procedures in view of these regulations.

Partnerships

• In March 2023, we entered into a license and collaboration agreement with a private entity pursuant to which we were granted an irrevocable, non-transferable right to commercialize its proprietary software, iBox, for the predictive analysis of post-transplantation kidney allograft loss in the field of transplantation for a period of four years with exclusive rights in the United States.
• In April 2020, we entered into a license agreement with Cornell University pursuant to which we were granted exclusive rights to four U.S. patents covering methods and technology for the measurement of gene expression in urine to diagnose kidney transplant rejection.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:58 UTC. This page is informational and not investment advice.